Complete Genomics Highlights New Products, Partnerships, First DNBSEQ User Group Meeting at ASHG 2025
BOSTON, Oct. 14, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a series of milestones at the American Society of Human Genetics (ASHG) Annual Meeting, Oct. 14–18, 2025 in Boston. At ASHG 2025, for the first time, Complete Genomics will host a DNBSEQ™ User Group Meeting to bring together researchers and customers to share best...
Pictor’s Proteomics Platform Offers Promising Advancement for Detecting Mycoplasma bovis in Cattle
New research highlights the Pictor PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced analytical performance through multiplexing and its potential to enhance global disease management. CARLSBAD, Calif., Oct. 14, 2025 /PRNewswire/ -- Mycoplasma bovis is a devastating pathogen that threatens cattle health and productivity worldwide. In the United States alone, economic losses due to...
Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the...
Cell Publishes Breakthrough Research Results of IASO Bio’s Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the Cell published results from the study evaluating its independently developed fully human anti-BCMA CAR-T cell therapy, Equecabtagene Autoleucel (Eque-cel), for the treatment of progressive multiple sclerosis...
Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix’s Biomimetic Collagen Rated “International Leading-Edge”
—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing, Zhejiang, bringing together a prestigious gathering of leading minds in the field. Attendees included Chinese Academy of Engineering academicians Zhang Xingdong and Wang Yingjun, Chinese Academy of Sciences academicians Chen Xuesi, Tang Peifu,...
India’s No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch ‘Hyundai Hope for Cancer’ to revolutionize Paediatric Cancer Care
CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras), India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pioneering initiative dedicated to transforming paediatric cancer care...
Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) in China to initiate clinical study in patients with advanced solid tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform....
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed -- -- Interim analysis...
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with...
Kyoto University Engineering Ph.D. Team Realizes Achievement Transformation in Chengdu; LivingPhoenix’s Biomimetic Collagen Rated “International Leading-Edge”
—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing, Zhejiang, gathering leading experts including academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, together with international figures such as U.S. National Academy of Engineering member...
